Claude Leclerc

Years Active: 2018-2022
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Paula Molinari, María Inés Crespo, Guido N Molina, Nicolás D Dho, Fábio V Marinho, Belkys Maletto, Claude Leclerc, Sergio C Oliveira, Oscar Taboga, Ignacio Cebrian, Gabriel Morón
TLR9 activation is required for cytotoxic response elicited by baculovirus capsid display. Immunology (2022)
Pierre Rosenbaum, Cécile Artaud, Sylvie Bay, Christelle Ganneau, Mario Campone, Suzette Delaloge, Carole Gourmelon, Delphine Loirat, Jacques Medioni, François Pein, Marie-Paule Sablin, Olivier Tredan, Andrea Varga, Claude Leclerc
The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients. Cancer immunology, immunotherapy : CII 69 (5) (2020)
Gilles Dadaglio, Catherine Fayolle, Marine Oberkampf, Alexandre Tang, Francesc Rudilla, Isabelle Couillin, Eirik A Torheim, Pierre Rosenbaum, Claude Leclerc
IL-17 suppresses the therapeutic activity of cancer vaccines through the inhibition of CD8+ T-cell responses. Oncoimmunology 9 (1) (2020)
Marine Oberkampf, Camille Guillerey, Juliette Mouriès, Pierre Rosenbaum, Catherine Fayolle, Alexandre Bobard, Ariel Savina, Eric Ogier-Denis, Jost Enninga, Sebastian Amigorena, Claude Leclerc, Gilles Dadaglio
Mitochondrial reactive oxygen species regulate the induction of CD8+ T cells by plasmacytoid dendritic cells. Nature communications 9 (1) (2018)

Claude Leclerc.css-eqlu8i{font-size:small;padding-left:4px;}